GlobeNewswire by notified

Equinor to commence second tranche of the 2022 share buy-back programme

Share

Equinor (OSE: EQNR, NYSE: EQNR) will commence on 16 May 2022 the second tranche of the share buy-back programme for 2022 of around USD 1.33 billion, as announced in relation with the first quarter results on 4 May 2022.

Execution of share buy-back from May 2022 and until April 2023 is subject to renewal of such authorisation to the Board of Directors from the annual general meeting 11 May 2022.

The second tranche of the share buy-back programme for 2022 is around USD 1.33 billion, including shares to be redeemed from the Norwegian State, and will end no later than 26 July 2022.

The annual share buy-back programme of USD 1.2 billion, introduced in June 2021, is expected to be executed when Brent Blend oil price is in or above the range of 50-60 USD/bbl, Equinor’s net debt ratio(1) stays within the communicated ambition of 15-30% and this is supported by commodity prices. Share buy-back can also be used more extensively to optimise capital structure.

The purpose of the share buy-back programme is to reduce the issued share capital of the company. All shares repurchased as part of the programme will be cancelled.

According to an agreement between Equinor and the Norwegian State, the Norwegian State will participate in share buy-backs on a proportionate basis, ensuring that its ownership interest in Equinor remains unchanged at 67%.

The share buy-back programme for 2022 will be structured into tranches where Equinor will buy back a certain value in USD of shares over a defined period. For the second tranche for 2022, running from 16 May 2022 until no later than 26 July 2022, Equinor is entering into a non-discretionary agreement with a third party who will make its trading decisions independently of the company.

In this second tranche, shares for up to around USD 440 million will be purchased in the market, implying a total second tranche of around USD 1.33 billion including redemption of shares from the Norwegian State.

The execution of further tranches of the share buy-back programme for 2022 will be notified to the market.

Further information about the share buy-back programme and the second tranche:

The second tranche of the share buy-back programme for 2022 is subject to renewal of the authorisation granted to the Board of Directors at the annual general meeting 11 May 2022 and this authorisation being registered in the Norwegian register for business enterprises. According to proposed authorisation to the annual general meeting on 11 May 2022, the maximum number of shares to be purchased in the market is 75 000 000, the minimum price that can be paid for shares is NOK 50, and the maximum price is NOK 1 000. The authorisation proposed will be valid until the earliest of 30 June 2023 and the annual general meeting in 2023.

As further described in the notice to the annual general meeting in 2022, Equinor has an agreement with the Norwegian State whereby the State will vote for the cancellation of shares purchased pursuant to the authorisation, and the redemption of a proportionate number of its shares in order to maintain its ownership share in the company. The price to be paid to the State for redemption of shares shall be the volume-weighted average of the price paid by Equinor for shares purchased in the market plus an interest rate compensation, adjusted for any dividends paid, in the period up until final settlement with the State.

In the second tranche in 2022, shares will be purchased on the Oslo Stock Exchange. Transactions will be conducted in accordance with applicable safe harbour conditions, and as further set out i.a. in the Norwegian Securities Trading Act of 2007, EU Commission Regulation (EC) No 2016/1052 and the Oslo Stock Exchange's Guidelines for buy-back programmes and price stabilisation February 2021.

The Board of Directors will propose to the annual general meeting in 2023 to cancel purchased shares in this second tranche and redeem the proportionate number of State shares. Any shares purchased in subsequent tranches will follow a similar process with cancellation and redemption at the following annual general meeting.

This is information that Equinor is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

* * *

(1) Non GAAP measure. Comparison numbers and reconciliation to IFRS are presented in the table Calculation of capital employed and net debt to capital employed ratio as shown under the Supplementary section in the financial statements.

* * *

Further information from:

Investor relations
Peter Hutton, senior vice president Investor Relations,
+44 7881 918 792 (mobile)

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584 (mobile)


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Havila Kystruten AS: Havila Pollux Cancels Upcoming Round Trip8.5.2024 23:15:38 CEST | Press release

Havila Pollux has been docked in Bergen since May 2nd for planned warranty work, after an electro motor supplying power to the propulsion system had to be replaced. In recent days, testing of the new electro motor has been conducted, during which a malfunction was discovered in a bearing in the underwater housing of one of the propellers (azimuth POD). Sailing the ship in service with this malfunction is not deemed safe, and the newly discovered issue must be rectified. Consequently, Havila Pollux will sail to GMC in Stavanger to be placed in dry-dock for the replacement of the propeller's underwater housing. This replacement is also considered warranty work. As a result, the upcoming round trip departing from Bergen on May 13th will be cancelled. Considering the necessary preparations by the Norwegian equipment supplier and the replacement of the underwater housing, it is expected that Havila Pollux will resume its regular service from Bergen no later than May 24th. All affected passe

Havila Kystruten AS: Havila Pollux kansellerer kommende rundtur8.5.2024 23:15:38 CEST | Pressemelding

Havila Pollux har siden 2. mai ligget til kai i Bergen for planlagte garantiarbeider, etter at en elektromotor som forsyner propellsystemet med kraft måtte byttes ut. De siste dagene har det vært utført testing av den nye elektromotoren, og i forbindelse med det er det oppdaget en feil på et lager i undervannshuset til den ene propellen (azimut POD). Å seile skipet i rute med denne feilen er ikke sikkerhetsmessig forsvarlig, og den nyoppdagede feilen må utbedres. Havila Pollux vil derfor seile til GMC i Stavanger for å settes i tørrdokk for bytte av undervannshuset til propellen. Denne utskiftingen anses også som garantiarbeid. Den kommende rundturen med avgang fra Bergen 13. mai vil derfor kanselleres. Hensyntatt nødvendige forberedelser fra den norske utstyrsleverandøren samt utskiftning av undervannshuset, er det er forventet at Havila Pollux er tilbake i rute igjen fra Bergen senest 24. mai. Alle berørte passasjerer blir kontaktet av Havila Kystruten. Kontakter: Administrerende dir

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update8.5.2024 22:15:38 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update. “At the upcoming 2024 ASCO meeting, we are looking forward to presenting multiple datasets including the first clinical data on safety and efficacy of petosemtamab in combination with pembrolizumab in previously untreated head and neck cancer. With p

CrossAmerica Partners LP Reports First Quarter 2024 Results8.5.2024 22:15:00 CEST | Press release

Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27.0 million compared to $31.2 million of Gross Profit for the First Quarter 2023 and First Quarter 2024 Gross Profit for the Retail Segment of $54.4 million compared to $50.8 million of Gross Profit for the First Quarter 2023Leverage, as defined in the CAPL Credit Facility, was 4.49 times as of March 31, 2024, compared to 4.21 times as of December 31, 2023The Distribution Coverage Ratio for the trailing twelve months ended March 31, 2024 was 1.37 times compared to 1

HiddenA line styled icon from Orion Icon Library.Eye